A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-04-14
Target enrollment:
Participant gender:
Summary
A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy
and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as
First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma
or Gastroesophageal Junction Adenocarcinoma.